Betting on Patriotism: What Makes a Military-Friendly Company
*By Michael Teich*
Patriotism can be good for profits, says Rich Cea, head of UBS's ETF product InsightShares.
Through its Patriotic Employers ETF, launched last January, UBS gives socially conscious investors an opportunity to support companies that recruit and hire military veterans. A portion of the revenue generated by the ETF will be donated to veteran charities.
"The companies that do well are the ones that invest in their programs to find leaders, culture carriers, and good team players," Cea told Cheddar on Monday.
He named Home Depot and IBM as examples of companies that do this particularly wellーand they're not the only ones. Topping
[Military.com's list](http://militaryfriendly.com/employers/?search=employers&industry=&revenue=&das_name=&mfe_verif=&rank_awards=Top+10) of military-friendly workplaces are insurance company State Farm and Big Four consulting firm PwC.
And it's not a matter of supporting veterans on principle, added Cea. Military veterans are often overlooked because hiring managers don't recognize their value in the workplace.
"We're looking for the companies that are doing the best job at hiring the best people for the job. Now, more and more, that's a challenge."
For the full interview, [click here](https://cheddar.com/videos/the-link-between-patriotism-and-investing).
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d